Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

C0460000

Carbidopa

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

(S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic acid monohydrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C10H14N2O4 · H2O
Número de CAS:
38821-49-7
Peso molecular:
244.24
MDL number:
MFCD00889211
UNSPSC Code:
41116107
PubChem Substance ID:
329774795
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

carbidopa

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O.C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O

InChI

1S/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1

InChI key

QTAOMKOIBXZKND-PPHPATTJSA-N

Gene Information

human ... DDC(1644)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

Carbidopa is a dopaminergic drug, which is known to inhibit the conversion of dopa to dopamine. It is used in combination with levodopa for the effective treatment of restless legs syndrome and periodic leg movements in sleep.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Carbidopa EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302,H319

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 3

1 of 3

Entacapone ≥98% (HPLC)

Sigma-Aldrich

SML0654

Entacapone

3,4-Dihidroxi-L-fenilalanina Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1271

3,4-Dihidroxi-L-fenilalanina

3,4-Dihidroxi-L-fenilalanina ≥98% (TLC)

Sigma-Aldrich

D9628

3,4-Dihidroxi-L-fenilalanina

The effect of carbidopa administration on urinary sodium excretion in man. Is dopamine an intrarenal natriuretic hormone?
Ball.G.S and Lee.R.M
British Journal of Clinical Pharmacology, 4(2), 115- 119 (1977)
Àlex Pericas et al.
Organic letters, 15(7), 1448-1451 (2013-03-13)
A stereoselective synthesis of L-carbidopa in seven steps and 50% overall yield from commercial compounds is described. The key step involves a highly enantioselective α-amination reaction of an acyclic β-ketoester with di-tert-butyl azodicarboxylate induced by europium and (R,R)-diphenyl-pybox.
Augmentation of the restless legs syndrome with carbidopa/levodopa
Allen.PR and Earley.JC
Sleep, 19(3), 205-213 (1996)
J T Hutton et al.
Neurology, 42(1 Suppl 1), 51-56 (1992-01-01)
Parkinson's disease patients treated chronically with levodopa often develop fluctuations in motor response. Motor fluctuations can be attributed in part to oscillating plasma levodopa concentrations. A controlled-release formulation containing 200 mg of levodopa and 50 mg of carbidopa provides superior
Egesta Lopci et al.
Cancer biotherapy & radiopharmaceuticals, 27(10), 729-733 (2012-10-06)
To verify the potential role and feasibility of carbidopa premedication in pediatric patients undergoing ¹⁸F-DOPA (Fluorine-18 fluorodihydroxyphenylalanine) PET scanning. For this limited study, 5 patients (M:F=3:2; mean age 4.8 years) with a positive history for neuroblastoma who had been referred
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico